Planned Parenthood v. Taft

CourtCourt of Appeals for the Sixth Circuit
DecidedFebruary 24, 2006
Docket04-4371
StatusPublished

This text of Planned Parenthood v. Taft (Planned Parenthood v. Taft) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Planned Parenthood v. Taft, (6th Cir. 2006).

Opinion

RECOMMENDED FOR FULL-TEXT PUBLICATION Pursuant to Sixth Circuit Rule 206 File Name: 06a0068p.06

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT _________________

X Plaintiffs-Appellees, - PLANNED PARENTHOOD CINCINNATI REGION, et al. - - - No. 04-4371 v. , > BOB TAFT, et al., - Defendants-Appellants. - N Appeal from the United States District Court for the Southern District of Ohio at Cincinnati. No. 04-00493—Susan J. Dlott, District Judge. Argued: December 7, 2005 Decided and Filed: February 24, 2006 Before: MOORE, ROGERS, and McKEAGUE, Circuit Judges. _________________ COUNSEL ARGUED: Anne Berry Strait, OFFICE OF THE ATTORNEY GENERAL, CHARITABLE LAW SECTION, Columbus, Ohio, for Appellants. Nicole G. Berner, PLANNED PARENTHOOD FEDERATION OF AMERICA, Washington, D.C., for Appellees. ON BRIEF: Anne Berry Strait, OFFICE OF THE ATTORNEY GENERAL, CHARITABLE LAW SECTION, Columbus, Ohio, Sharon A. Jennings, Holly J. Hunt, OFFICE OF THE ATTORNEY GENERAL OF OHIO, CONSTITUTIONAL OFFICES SECTION, Columbus, Ohio, for Appellants. Nicole G. Berner, PLANNED PARENTHOOD FEDERATION OF AMERICA, Washington, D.C., Alphonse A. Gerhardstein, GERHARDSTEIN, BRANCH & LAUFMAN, Cincinnati, Ohio, Roger K. Evans, Mimi Y.C. Liu, PLANNED PARENTHOOD FEDERATION OF AMERICA, New York, New York, Jeffrey M. Gamso, AMERICAN CIVIL LIBERTIES UNION OF OHIO FOUNDATION, Cleveland, Ohio, Jessie Hill, CASE WESTERN RESERVE UNIVERSITY SCHOOL OF LAW, Cleveland, Ohio, for Appellees. Peter O. Safir, Kelly A. Falconer, COVINGTON & BURLING, Washington, D.C., for Amicus Curiae. McKEAGUE, J., delivered the opinion of the court, in which ROGERS, J., joined. MOORE, J. (p. 13), delivered a separate opinion concurring in part. _________________ OPINION _________________ McKEAGUE, Circuit Judge. Plaintiffs challenge an Ohio statute which prohibits the off-label use of the abortion drug mifepristone (more commonly known as RU-486). The district court granted a preliminary injunction enjoining enforcement of the statute on two alternative grounds. The State timely

1 No. 04-4371 Planned Parenthood, et al. v. Taft, et al. Page 2

filed an interlocutory appeal. For the following reasons, we hold that the district court’s primary holding was error, but affirm the reasoning of the district court’s alternative holding. Nevertheless, we vacate the district court’s order in part and remand for consideration of the appropriate scope of injunctive relief in light of the United States Supreme Court’s recent decision in Ayotte v. Planned Parenthood of Northern New England, — U.S. —, 126 S. Ct. 961 (2006). I. Until 2000 most first trimester abortions in this country were surgical abortions performed by vacuum aspiration or curettage. In September of 2000, the Food and Drug Administration (“FDA”) approved mifepristone, a pill used to induce an abortion without surgical intervention, for manufacture and use in the United States. This approval was based on clinical trials which involved the oral ingestion of 600 mg of mifepristone followed two days later by the oral ingestion of 0.4 mg of misoprostol.1 Upon examining the results of these trials, the FDA concluded that this regimen was a safe and effective method of medical abortion when employed up through forty-nine days’ gestation. Consequently, the FDA approved the use of mifepristone. The FDA labeling and approval letter indicated that the appropriate treatment regimen was to administer 600 mg of mifepristone orally followed by 0.4 mg of misoprostol administered orally two days later and that mifepristone was not to be administered after forty-nine days’ gestation. Absent state regulation, once a drug has been approved by the FDA, doctors may prescribe it for indications and in dosages other than those expressly approved by the FDA. This is a widely employed practice known as “off-label” use. Off-label use does not violate federal law or FDA regulations because the FDA regulates the marketing and distribution of drugs in the United States, not the practice of medicine, which is the exclusive realm of individual states. Subsequent to the clinical trials relied upon by the FDA, other trials were conducted experimenting with different possible regimens for administering mifepristone and misoprostol. As a result of this research, an off-label protocol was developed consisting of 200 mg of mifepristone administered orally followed one to three days later by 0.8 mg of misoprostol administered vaginally. This regimen is employed up to sixty-three days’ gestation and is known as the Schaff protocol after the doctor whose research primarily led to its development. The Schaff protocol is the method of medical (i.e., non-surgical) abortion recommended by the National Abortion Federation and Planned Parenthood Federation of America and has come to be widely employed across the United States.2 In 2004, the Ohio General Assembly enacted H.B. 126 (“the Act”) to regulate the use of mifepristone in Ohio. Specifically, the Act provides: No person shall knowingly give, sell, dispense, administer, otherwise provide, or prescribe RU-486 (mifepristone) to another for the purpose of inducing an abortion . . . unless the person . . . is a physician, the physician satisfies all the criteria established by federal law that a physician must satisfy in order to provide RU-486 (mifepristone) for inducing abortions, and the physician provides the RU-486 (mifepristone) to the other person for the purpose of inducing an abortion in accordance with all provisions of federal law that govern the use of RU-486 (mifepristone) for inducing abortions.

1 The mifepristone is an abortifacient which terminates the pregnancy by detaching the gestational sac from the uterine wall. The misoprostol is a prostaglandin which induces the contractions necessary to expel the fetus and other products of conception from the uterus. 2 After this appeal was briefed, the American College of Obstetricians and Gynecologists (ACOG) issued a practice bulletin stating that compared with the FDA protocol the Schaff protocol is “associated with a decreased rate of continuing pregnancies, decreased time to expulsion, fewer side effects, improved complete abortion rates, and lower cost for women with pregnancies up to 63 days’ gestation.” The previous relevant ACOG practice bulletin from 2001 had only recommended using the FDA protocol and specifically stated that medical abortion should not be performed after forty-nine days’ gestation. No. 04-4371 Planned Parenthood, et al. v. Taft, et al. Page 3

Ohio Rev. Code Ann. § 2919.123(A). The Act defines “federal law” as, “any law, rule, or regulation of the United States or any drug approval letter of the food and drug administration of the United States that governs or regulates the use of RU-486 (mifepristone) for the purpose of inducing abortions.” Ohio Rev. Code Ann. § 2919.123(F). This arguably requires doctors who prescribe mifepristone for the purpose of inducing an abortion to do so only in accordance with the indication, regimen and distribution restrictions approved by the FDA. In other words, the Act prohibits the “off-label” use of mifepristone. According to the State, the Act was passed because abortion providers in Ohio were openly using the Schaff protocol and “because legislators became aware that several women had died or been severely injured recently as a result of their use of mifepristone.”3 Ohio legislators concluded that the FDA had only approved one specific protocol for the administration of mifepristone because that was the only safe and effective protocol. Therefore, they banned all other uses of mifepristone to protect Ohio women from unsafe and ineffective mifepristone protocols.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Ex Parte Young
209 U.S. 123 (Supreme Court, 1908)
Hormel v. Helvering
312 U.S. 552 (Supreme Court, 1941)
Guste v. Jackson
429 U.S. 399 (Supreme Court, 1977)
Morales v. Trans World Airlines, Inc.
504 U.S. 374 (Supreme Court, 1992)
Planned Parenthood of Southeastern Pa. v. Casey
505 U.S. 833 (Supreme Court, 1992)
Stenberg v. Carhart
530 U.S. 914 (Supreme Court, 2000)
Scheidler v. National Organization for Women, Inc.
537 U.S. 393 (Supreme Court, 2003)
Branch v. Smith
538 U.S. 254 (Supreme Court, 2003)
United States v. Booker
543 U.S. 220 (Supreme Court, 2004)
Ayotte v. Planned Parenthood of Northern New Eng.
546 U.S. 320 (Supreme Court, 2006)
Michigan State Afl-Cio v. Miller
103 F.3d 1240 (Sixth Circuit, 1997)
Paccar Inc. v. Telescan Technologies, L.L.C.
319 F.3d 243 (Sixth Circuit, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
Planned Parenthood v. Taft, Counsel Stack Legal Research, https://law.counselstack.com/opinion/planned-parenthood-v-taft-ca6-2006.